Dear colleagues,

With great sadness, I share the news of the passing of Misha Blagosklonny, an extraordinary scientist whose highly original contributions significantly advanced cancer and aging biology research. Roswell was fortunate to have him as a faculty member in the Department of Cell Stress Biology during several exceptionally productive years, during which he published over 100 papers. Misha was also widely known as the founding editor of several prominent peer-reviewed journals, including Cell Cycle, Oncotarget, Oncoscience, and Aging.

He was always a visionary thinker, often ahead of his time, with ideas that pushed the boundaries of our field. Tragically, Misha succumbed to metastatic cancer after about two years of remission following an initial positive response to targeted therapies. Even in his final days, he continued to collaborate actively and creatively with his physicians, as evidenced in his thoughtful posts on X (https://x.com/blagosklonny?lang=en).

Misha will be remembered as one of the most uniquely gifted oncologists of our time.

For more details about his professional life, please visit: Dr. Blagosklonny.

Sincerely,

Andrei

Andrei V. Gudkov
PhD, DSci, Professor and Garman Family Chair in Cell Stress Biology, Senior Vice President for Basic Research of Roswell Park Comprehensive Cancer Center (RPCI), Buffalo, NY. His academic degrees in experimental oncology and molecular biology were received in former USSR from National Cancer Center and Moscow State University. He is co-founder and Chief Scientific Officer of Cleveland BioLabs, Inc. and Tartis, Inc. His area of general research interest includes drug discovery, gene discovery, molecular targets for cancer treatment.

Barzilai DA. Mikhail ‘Misha’ Blagosklonny’s enduring legacy in geroscience: the hyperfunction theory and the therapeutic potential of rapamycin. Aging (Albany NY). 2025;:17:1-15. doi: 10.18632/aging.206189 [PubMed]

The untimely passing of Dr. Mikhail “Misha” Blagosklonny has left a lasting void in geroscience and oncology. This review examines his profound contributions, focusing on his pioneering the Hyperfunction Theory and his advocacy for rapamycin, an mTOR inhibitor, as a therapeutic agent for lifespan extension. Contrary to traditional damage-centric models, the Hyperfunction Theory rejects damage accumulation as the primary driver of aging. Instead, it redefines aging as a quasi-programmed process driven by the persistent, excessive activity of growth-promoting pathways beyond their developmental roles, leading to age-related pathologies. We explore how Blagosklonny’s insights predict rapamycin’s ability to decelerate aging by modulating excessive mTOR signaling, supported by empirical evidence across multiple physiological systems, including immune, cardiovascular, cognitive, and oncologic health. His forward-thinking approach, advocating for the cautious clinical use of rapamycin and suggesting personalized, preventive, and combination therapy strategies, has catalyzed interest in translational geroscience. This review synthesizes Blagosklonny’s legacy, presenting rapamycin as a foundational pharmacological intervention with potential in managing age-related decline and extending healthspan, and underlines his impact in shifting aging research from theoretical frameworks to actionable interventions. Blagosklonny’s work remains an enduring inspiration, paving the way toward treating aging as a modifiable condition.

FULL TEXT

David Barzilai
Founder and CEO of Barzilai Longevity Consulting (barzilaiconsulting.com) and serves on the academic staff at the Geneva College of Longevity Science. A board-certified physician and a pioneer in longevity and lifestyle medicine, Dr. Barzilai is also a Diplomate of the American Board of Lifestyle Medicine, specializing in healthy lifestyle practices. He earned his MD and PhD in Health Services Research (Department of Epidemiology & Biostatistics) from Case Western Reserve University. Dr. Barzilai completed his Dermatology Residency at The Warren Alpert Medical School of Brown University and holds an MBA from the Isenberg School of Management, UMass Amherst.

David A.Sinclair
Editor-in-Chief of Aging (Aging-US). Professor of Pathology and Co-Director of the Glenn Laboratories for Aging Research at Harvard Medical School, Boston, MA. Dr. Sinclair obtained a BSc (1st class honors) and a Ph.D. from the University of New South Wales in Sydney, Australia. From 1995-1999, he worked as a postdoctoral researcher with Lenny Guarente at M.I.T. Dr. Sinclair has received awards including The Australian Commonwealth Prize, a Helen Hay Whitney Postdoctoral Award, a Leukemia Society Fellowship, a Ludwig Scholarship, a Harvard-Armenise Fellowship, an American Association for Aging Research Fellowship, and a Fellowship and Senior Scholarship from the Ellison Medical Foundation.